The PreDiCT-TB consortium and the Critical Path to TB Regimens have announced the signing of a memorandum of understanding outlining plans to co-ordinate their activities in the area of TB drug development methodology.

The University of Liverpool has been awarded funding to determine whether differences in our genes determine how patients respond to drugs used to treat Tuberculosis (TB) in Sub-Saharan Africa.